Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30151383 | 1.00 | NTRK1 (0.65) | NTRK1JAK2 | |
| SCHEMBL17820710 | 1.00 | NTRK1 (0.65) | NTRK1JAK2 | |
| SCHEMBL30151382 | 0.92 | NTRK1 (0.73) | NTRK1JAK2 | |
| SCHEMBL30343339 | 0.88 | NTRK1 (0.58) | NTRK1JAK2 | |
| SCHEMBL17821068 | 0.88 | NTRK1 (0.58) | NTRK1JAK2 | |
| SCHEMBL17820606 | 0.88 | NTRK1 (0.58) | NTRK1JAK2 | |
| SCHEMBL30511995 | 0.87 | NTRK1 (0.64) | NTRK1JAK2 | |
| SCHEMBL29497146 | 0.86 | NTRK1 (0.57) | NTRK1JAK2 | |
| SCHEMBL462409 | 0.85 | NTRK1 (0.68) | NTRK1JAK2 | |
| SCHEMBL17820745 | 0.85 | NTRK1 (0.60) | NTRK1JAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4420732-A2 | FUSED RING HETEROARYL COMPOUNDS AND THEIR USE AS TRK INHIBITORS | CMG Pharmaceutical Co., Ltd. (KR) | 2024-08-28 | — | — | EP | disclosed |
| EP-3233863-B1 | FUSED RING HETEROARYL COMPOUNDS AND THEIR USE AS TRK INHIBITORS | CMG PHARMACEUTICAL CO LTD (KR) | 2024-04-10 | — | — | EP | disclosed |
| US-20230227460-A1 | FUSED AZA-HETEROCYCLIC AMIDE COMPOUND AND USE THEREOF | CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY (SHIJIAZHUANG) CO., LTD (CN) | 2023-07-20 | — | — | US | disclosed |
| US-20230227460-A1 | FUSED AZA-HETEROCYCLIC AMIDE COMPOUND AND USE THEREOF | CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY (SHIJIAZHUANG) CO., LTD (CN) | 2023-07-20 | — | — | US | disclosed |
| US-20230227460-A1 | FUSED AZA-HETEROCYCLIC AMIDE COMPOUND AND USE THEREOF | CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY (SHIJIAZHUANG) CO., LTD (CN) | 2023-07-20 | — | — | US | disclosed |
| WO-2023083357-A1 | SALT OF NITROGEN-CONTAINING FUSED HETEROCYCLIC AMIDE COMPOUND, CRYSTAL FORM THEREOF, AND USE THEREOF | 石药集团中奇制药技术（石家庄）有限公司 | 2023-05-19 | — | — | WO | disclosed |
| WO-2023083362-A1 | DRUG FOR TREATING TUMORS | 石药集团中奇制药技术（石家庄）有限公司 | 2023-05-19 | — | — | WO | disclosed |
| WO-2023083356-A1 | NITROGEN FUSED-HETEROCYCLIC AMIDE COMPOUND IN SOLID FORM AND USE THEREOF | 石药集团中奇制药技术（石家庄）有限公司 | 2023-05-19 | — | — | WO | disclosed |
| WO-2023083362-A1 | DRUG FOR TREATING TUMORS | 石药集团中奇制药技术（石家庄）有限公司 | 2023-05-19 | — | — | WO | disclosed |
| EP-4151635-A1 | FUSED AZA-HETEROCYCLIC AMIDE COMPOUND AND USE THEREOF | CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. (CN) | 2023-03-22 | — | — | EP | disclosed |
| WO-2021228248-A1 | FUSED AZA-HETEROCYCLIC AMIDE COMPOUND AND USE THEREOF | 石药集团中奇制药技术（石家庄）有限公司 | 2021-11-18 | — | — | WO | disclosed |
| EP-3233863-A1 | FUSED RING HETEROARYL COMPOUNDS AND THEIR USE AS TRK INHIBITORS | CMG Pharmaceutical Co., Ltd. (KR) | 2017-10-25 | — | — | EP | disclosed |
| US-9701681-B2 | Fused ring heteroaryl compounds and their use as Trk inhibitors | CMG PHARMACEUTICAL CO., LTD. (KR) | 2017-07-11 | — | — | US | disclosed |
| US-9701681-B2 | Fused ring heteroaryl compounds and their use as Trk inhibitors | CMG PHARMACEUTICAL CO., LTD. (KR) | 2017-07-11 | — | — | US | disclosed |
| US-9701681-B2 | Fused ring heteroaryl compounds and their use as Trk inhibitors | CMG PHARMACEUTICAL CO., LTD. (KR) | 2017-07-11 | — | — | US | disclosed |
| WO-2016097869-A1 | FUSED RING HETEROARYL COMPOUNDS AND THEIR USE AS TRK INHIBITORS | CMG PHARMACEUTICAL CO., LTD. (KR) | 2016-06-23 | — | — | WO | disclosed |
| US-20160168156-A1 | FUSED RING HETEROARYL COMPOUNDS AND THEIR USE AS TRK INHIBITORS | HANDOK INC. (KR) | 2016-06-16 | — | — | US | disclosed |
| US-20160168156-A1 | FUSED RING HETEROARYL COMPOUNDS AND THEIR USE AS TRK INHIBITORS | HANDOK INC. (KR) | 2016-06-16 | — | — | US | disclosed |
| US-20160168156-A1 | FUSED RING HETEROARYL COMPOUNDS AND THEIR USE AS TRK INHIBITORS | HANDOK INC. (KR) | 2016-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230227460-A1 | FUSED AZA-HETEROCYCLIC AMIDE COMPOUND AND USE THEREOF | ROS1, ALK, ROR1 | NTRK1 7/4885JAK2 380/4885 |
| US-20160168156-A1 | FUSED RING HETEROARYL COMPOUNDS AND THEIR USE AS TRK INHIBITORS | NR4A3, NR4A1, NR3C1 | NTRK1 5/4885JAK2 1535/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.